[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corneal-epithelial-wound-healing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corneal-epithelial-wound-healing":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100581752","phase-2-lacripep-for-corneal-wound-healing-study-100581752",false,"NCT06854393","Lacripep for Corneal Wound Healing Study","Lacripep, a Novel Investigational Agent, for Corneal Wound Healing and Ocular Surface Homeostasis","Inclusion Criteria:\n\n1. Male or female, of any race, 21 years old and older\n2. Active-duty U.S. military service members or their dependents eligible for care at Alexander T. Augusta Military Medical Center for 6-month period postoperatively\n3. Desiring refractive correction of myopia up to -4.00 diopters (D) sphere with or without astigmatism 0 to -1.50 D and up to -4.00 D manifest spherical equivalent in both eyes\n4. Stable refraction for the past year as demonstrated by a change in manifest refractive spherical equivalent of ≤ 0.50 diopters (D) in both eyes\n5. CDVA of at least 20\u002F20 in both eyes\n6. Elected to undergo bilateral PRK\n7. Able to meet follow up requirements for up to 6-month period post-operatively\n\nExclusion Criteria:\n\n1. Calculated ablation depth of greater than 75 microns or other conditions in either eye which in the judgement of the investigators will require use of prophylactic MMC\n2. Signs of unstable or progressive myopia, keratoconus or keratoconus suspect in either eye\n3. Abnormal corneal topographic findings in either eye e.g., keratoconus, pellucid marginal degeneration\n4. Treatment targeted for monovision\n5. Signs and symptoms of dry eye based on: (a) Corneal fluorescein staining total score ≥4 in the National Eye Institute (NEI)\u002FIndustry Workshop scale in either eye, (b) Anethetized Schirmer test score ≤5 mm\u002F5 minutes in either eye, (c) Symptom score ≤40 using the Symptom Assessment in Dry Eye (SANDE) questionnaire in either eye\n6. Female subjects who are pregnant, breastfeeding or intend to become pregnant during the study. Pregnancy and breastfeeding are contraindications to refractive surgery in general, including PRK, whether participating in this study or not.\n7. Residual, recurrent or active ocular diseases or corneal abnormalities in either eye such as iritis, uveitis, keratoconjunctivitis sicca, herpetic keratitis, vernal conjunctivitis, lagophthalmos, corneal scarring, anterior basement membrane disease, recurrent erosions, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts\n8. Previous corneal or intraocular surgery in either eye for refractive or therapeutic purposes\n9. Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane®), amiodarone hydrochloride (Cordarone®) and\u002For sumatriptan (Imitrex®) (other medications in the same family as Imitrex will still be allowed)\n10. Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.\n11. Individuals not legally competent to provide informed consent (e.g., incapacitated individuals, cognitively impaired) will not be enrolled. All subjects must provide consent to participate in the study","ALL","21 Years","55 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The objective of this study is to evaluate the safety and effectiveness of Lacripep as a therapy for superficial corneal injury repair after Photorefractive keratectomy (PRK).",[27],"Corneal Epithelial Wound Healing",[29,30,31,32,33],"Cornea","Wound healing","PRK","Lacritin","Lacripep","RECRUITING","2026-03-24",{"date":37,"type":38},"2026-03-25","ACTUAL",{"date":40,"type":38},"2025-05-23",{"date":42,"type":21},"2027-09",{"name":44,"class":45},"Henry M. Jackson Foundation for the Advancement of Military Medicine","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100589625","phase-4-efficacy-of-topical-insuline-in-corneal-epithelial-healing-post-prk-100589625","NCT06956846","Efficacy of Topical Insuline in Corneal Epithelial Healing Post PRK","Efficacy of Topical Insuline Drops in Corneal Epithelial Healing Post PRK in Non Diabetic Patients: an Randomized-controlled Trial","Inclusion Criteria:\n\n* Myopic or astigmatic patient undergoing excimer laser PRK\n\nExclusion Criteria:\n\n* diabetes mellitus prior ocular surgery ocular surface disease (including dry eye disease, history of herpetic keratitis) previous ocular trauma use of systemic corticosteroids",true,"18 Years",{"count":57,"type":21},100,[59],"PHASE4","A prospective randomized double-blind controlled trial will be conducted. The informed consent of each patient will be obtained prior to the procedure.\n\nAll patients will undergo a classic PRK procedure\n\nPatients will be instructed to use eye drops blindly in both eyes at a frequency of six times daily:\n\n* In one eye: Insulin drops formulated by combining regular human insulin with artificial tears containing polyethylene glycol (PEG 400) 0,25% at a concentration of 1 unit per milliliter.\n* In the other eye: Placebo drops containing only artificial tears. For the double-blind trial, two identical vials will be provided to each patient: one labeled R (for the right eye) and one labeled L (for the left eye). Using the bloc randomization method, the pharmacy will be the only entity aware of the composition of each vial, ensuring that 50% of patients use insulin drops in the right eye and 50% in the left eye.\n\nEvery week the drops will be prepared one day prior to the PRK procedure and will be stored in a refrigerator, to be used within one week of their preparation date.\n\nPatients will be examined by two ophthalmology residents on days 2 and 4 post-operatively.\n\nThe size of the epithelial defect in both eyes will be measured using the ImageJ software. Thus, the primary outcome of the study is the ulceration closure rate: the smaller the defect, the faster the epithelial healing is.\n\nAdditionally, a comparison of subjective symptoms reported by the patient in each eye will be recorded.",[27],"NOT_YET_RECRUITING","2025-04-25",{"date":65,"type":38},"2025-05-04",{"date":63,"type":21},{"date":68,"type":21},"2025-07",{"name":70,"class":45},"Hotel Dieu de France Hospital",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100579308","phase-4-evaluation-of-dexpanthenol-and-hyaluronic-acid-eye-drops-on-corneal-epithelialization-after-trans-epithelial-prk-100579308","NCT06822608","Evaluation of Dexpanthenol and Hyaluronic Acid Eye Drops on Corneal Epithelialization After Trans Epithelial PRK","Evaluation of a Fixed Combination of Dexpanthenol and Hyaluronic Acid Preservative-free Eye Drops on Corneal Epithelialization After Trans Epithelial PRK: a Prospective, Contralateral, Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* Male and female subjects aged ≥ 18\n* Bilateral trans PRK for the correction of myopia using the Schwind Amaris 1050RS laser at the same treatment zone (6.5mm)\n* Signed written informed consent Ability and willingness to participate in all examinations\n\nExclusion Criteria:\n\n* Known hypersensitivity or intolerance to any component of the product\n* Previous refractive surgery\n* Myopic refractive error higher than 8.00 diopters (D)\n* Anisometropia higher than 2.00 D\n* Ocular or systemic disease that could affect epithelial healing",{"count":79,"type":21},68,[59],"The aim of this prospective, contralateral, randomized, double-blind, placebo-controlled study is the evaluation of the performance of a fixed combination of dexpanthenol and hyaluronic acid preservative-free eye artificial tears eye drops, in corneal wound healing after trans epithelial photorefractive keratectomy. One eye of each patient, randomly determined, will be assigned to receive artificial tears containing a combination of dexpanthenol-hyaluronic acid (study group) while the fellow eye will receive Placebo \u002F identical combination containing the same ingredients and hyaluronic acid without dexpanthenol (control group). The drops will be applied hourly postoperatively, starting one hour after the surgery. All subjects will be treated until the day of complete reepithelialization or a maximum of 7 days postoperatively. Researchers will compare the epithelialization between the two eyes. The primary endpoint is the time to reepithelialization.The secondary endpoints are the intra-individual differences measured in each eye in terms of epithelial defect size in each visit, subjective evaluation of pain (discomfort) and subjective evaluation of vision.",[27],[84,85,86,87,88,89,90,91,92,93],"epithelial defect","re-epithelialization","reepithelialization","dexpanthenol","trans - PRK","contrallateral study","double-blinded study","prospective study","corneal healing","corneal epithelium healing","2025-02-11",{"date":96,"type":38},"2025-02-12",{"date":98,"type":21},"2025-02",{"date":100,"type":21},"2026-01",{"name":102,"class":45},"National and Kapodistrian University of Athens"]